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Abstract Myristicin (5-allyl-1-methoxy-2,3-methylenodi-
oxybenzene) is the main component of nutmeg (Myristica
fragrans Houtt.) essential oil. The increasing use of
myristicin as a cheap hallucinogenic intoxicant, frequently
causing fatal cases of myristicin poisoning, requires new
methods for determination of this compound in blood. This
report describes the rapid, simple, and useful procedure for
myristicin analysis in human serum, involving myristicin–
protein complex degradation before chromatographic
analysis. The developed method is characterized by a high
recovery (above 99 %), a low detection limit (6.0 ng/g)
and good repeatability (average RDS of 2.01 %).




zene) is the main component of nutmeg essential oil [1],
which exists in the nutmeg nut (Myristica fragrans Houtt.)
and in mace, the waxy red covering of the nutmeg seed.
Readily accessible on local markets, these spices have, at
times, been drugs of abuse. On the other hand, nutmeg and
mace are used in Asia as traditional medicines treating
stomach cramps, diarrhea, and rheumatism. Information
currently available on myristicin explains why its effects
range from harmful to beneficial. As reported in the liter-
ature [2], this alkenylbenzene acts as a serotonin receptor
antagonist and as a hallucinogenic compound. Moreover, it
induces: neurotoxicity in human neuroblastoma SK-N-SH
cells [3]; P450 liver enzyme in several families of rat,
including the P450 1A enzyme [4], which is also induced
by polyaromatic hydrocarbons, dioxins, and polychlori-
nated biphenyls; glutathione S-transferase [5] and forms
DNA adducts in rodent livers. The ability to form DNA
adducts is a common property of most chemical carcino-
gens and their metabolites [6]. Several tests have shown
myristicin to be a weak monamine oxidase (MAO) inhib-
itor [7]. Acutely toxic doses of myristicin can cause organ
damage [8]. Myristicin poisoning can lead to many health
problems such as convulsions, delirium, blurred vision,
palpitations, nausea, dehydration, general body pain, and
others [9]. Those symptoms usually occur 3–6 h after the
ingestion of myristicin or foodstuffs containing it, and
persist up to 72 h [10]. In recent years, many cases of
nutmeg poisoning have been reported, including several
fatal myristicin cases [11–13]. Such poisonings can result
not only from the toxic effect of myristicin itself but also
from the combined toxic effects of its use with other sub-
stances [12]. Because of potential widespread human
exposure through foods and beverages and the possibility
of adverse effects in diverse populations, myristicin was
presented to the Chemical Selection Working Group
(CSWG) for review.
Two publications describing myristicin determination in
biofluid can be found in the literature [14, 15]. The first
concerns the myristicin metabolism in rats, but the results
presented in the article were not obtained in a quantitative
fashion. As a result, it is difficult to judge the method used
for myristicin estimation in the reported study [14].
Moreover, the described method involves a derivatization
process, which is frequently inconvenient in GC analysis
(the formation of deposits in the liner of GC injector or in
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chromatographic column). In the second study [15], a
method for HPLC determination of myristicin in rat serum
is described. The procedure involves deproteinization,
separation, and fractionation concentration of myristicin by
appropriate switching of columns in the HPLC system.
However, it should be stressed that the removal of serum
proteins in the HPLC process can lead to the loss of ana-
lytes forming analyte–protein complexes. The present
report describes the GC procedure for myristicin analysis
in human plasma. The procedure involves a protein pre-
cipitation process, which generally degrades drug–protein
complexes, and solid-phase extraction (SPE) isolation of
myristicin from the examined materials. The proposed
analytical approach can be considered as a method of
choice for the estimation of myristicin in human fluids.
Materials and methods
Chemicals and reagents
Hexane and ethanol, both of analytical grade, were sup-
plied by POCH (Gliwice, Poland). The Sepra C18-E sor-
bent (50 lm, 65A˚) used in the SPE process was purchased
from Phenomenex (Torrance, CA, USA). Myristicin, of
analytical standard, was supplied by Fluka (Buchs, Swit-
zerland). Blood for the validation procedure and blood
samples containing myristicin were obtained from volun-
teers. Water was purified on a Milli-Q system (Millipore,
Bedford, MA, USA).
Sample preparation
Preparation of blood samples
Myristicin-free and myristicin-containing blood samples,
obtained from healthy volunteers recruited from our labo-
ratory, were obtained from forearm vein using Sarstedt
blood collection systems. Heparin sodium was used as an
anticoagulant. Myristicin was administered to the volun-
teers in the form of an alcoholic drink. Twenty grams of the
myristicin solution (5 mg/g) was consumed by each vol-
unteer 1 h before blood sampling.
All volunteers gave consent to participate in the studies
and were made aware of the option to withdraw from
further participation in the study at any time and for any
reason. Each of them signed a consent form for processing
of the experimental data obtained in this study.
Standard plasma solutions
To estimate myristicin recovery from plasma in the applied
method, eight plasma samples containing 0.01, 0.1, 1, 10,
25, 50, 75, and 100 lg/g, respectively (same concentrations
used for equipment calibration—see Chromatographic
analysis below), were prepared. Pure plasma samples were
spiked with myristicin solutions in ethanol/water mixture
(30/70 % v/v). In each case, the volume of the spiking
solution was less than 80 ll.
Myristicin isolation by SPE
To eliminate eventual loss of myristicin caused by its
binding with plasma proteins, 1.5 ml of ethanol was added
to 1 ml of plasma sample in a 4-ml glass vial and vortexed
for 5 min. After centrifugation (945 g for 15 min), 1 ml of
supernatant was mixed with 1.5 ml of water and 2 ml of
the obtained solution was transferred into an SPE cartridge
containing 0.2 g of SepraC18-E. Before loading, the car-
tridge was washed with 5 ml of n-hexane and then vac-
uum-dried (ca. 5 min). After removal of the loading
solvent from the SPE bed, the remaining components were
eluted into a calibrated flask with 2 ml of n-hexane and the
solution was analyzed by GC. The SPE process was car-
ried out using the SPE vacuum chamber (SPE-12G
from J.T.Baker USA) at an eluent velocity of 1 drop per
second.
Myristicin isolation by liquid–liquid extraction (LLE)
The mixture of plasma sample (1 ml) and hexane (1 ml)
was vigorously shaken for 10 min at 2000 rpm. After
phase separation (centrifugation), the hexane layer was
subjected to GC analysis.
Chromatographic analysis
The amount of myristicin was estimated using a GC with
flame ionization detection (FID) (GC 2010, Shimadzu,
Kyoto, Japan). To confirm the peak purity, each sample
was also analyzed by GC-mass spectrometry (GC/MS
QP2010, Shimadzu, Kyoto, Japan).
For identification of SPE extracts, a ZB5-MS fused-
silica capillary column (30 m 9 0.25 mm i.d., 0.25 ll film
thickness; Phenomenex, USA) was used. Helium (grade
5.0) was used as carrier gas. A 1-ll aliquot of the sample
was injected using an AOC-20i type autosampler. The
injector’s temperature was 310 C. The following tem-
perature program was applied: 1 min at 50 C, followed by
a linear temperature increase up to 250 C at 6 C /min.
The mass spectrometer was operated in EI mode at 70 eV;
the ion source temperature was 220 C. The mass spectra
were measured in the range 35–360 amu. Qualitative
analysis was conducted by comparing the retention indices
and MS spectra for the obtained peaks with analogous data
from NIST’05 to Adams databases.
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Quantification of extracts was performed by injecting
1 ll of the sample using the same autosampler and capil-
lary column. The temperature program during GC-FID
separation was the same as for GC-MS.
Myristicin peak identification was carried out by com-
paring the GC retention index with those from GC-MS and
with the retention data for myristicin standard.
The applied GC-FID equipment was calibrated using
myristicin standard solutions. The working solutions were
obtained by serial dilutions of the stock solution with
hexane to obtain the following myristicin concentration:
0.01, 0.1, 1, 10, 25, 50, 75, and 100 lg/g.
Results and discussion
Figure 1 presents chromatograms for myristicin analytical
standard (Fig. 1a), SPE extracts from blank plasma
(Fig. 1b), and a plasma sample spiked with alcohol solu-
tion of myristicin standard (Fig. 1c), with the two latter
results were obtained according to the presented procedure.
Figure 1d shows the chromatogram for the LLE extract
from blank plasma, while Fig. 1e shows the additional
chromatogram for the SPE extract from the plasma of a
volunteer who consumed an alcohol solution of myristicin.
As appears from the figure, the applied chromatographic
conditions allow for sufficient resolution of myristicin from
sample matrix peaks, both in the SPE and LLE procedures.
However, the use of SPE seems better due to the lack of
peaks occurring in the vicinity of myristicin retention in
this procedure. In the case of LLE, the extract contains
some cholesteric derivatives (Fig. 1d), the presence of
which requires more frequent cleaning of the GC injector
and leads to faster column deterioration. The identity and
purity of the myristicin peak were confirmed by the MS
spectra and the value of the retention index (1520), which
is exactly the same as the literature value [16].
Figure 2 illustrates the calibration plot for myristicin in
the concentration range from 10 ng/g to 100.0 lg/g. The
resultant calibration curve shows excellent linearity with
R2 = 0.9998. The intercept value (48.1) equals 10 % of the
detection limit. The obtained value exceeds the FDA
requirements of R2 C 0.999 from a minimum of five
observations [17, 18].
The precision and accuracy of the SPE step of the
applied procedure are shown in Table 1. The presented
data were obtained by five successive analyses for each
sample spanning the range of the calibration curve. The
examined method is characterized by very high SPE
recovery (mean recovery 99.08 %) and exhibits excellent
precision. The average precision of the SPE step deter-
mined as RSD for the samples at low, intermediate, and
high myristicin concentrations is 2.01 %.
Fig. 1 GC chromatograms of: a Myristicin analytical standard,
b SPE extract from blank plasma sample, c SPE extract from plasma
sample spiked with alcoholic solution of myristicin standard, d LLE
extract from blank plasma, e SPE extract from plasma of a volunteer
who consumed alcoholic solution of myristicin
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In order to estimate the limit of detection (LOD) and the
limit of quantitation (LOQ), SPE extracts from plasma
samples spiked with the myristicin standard were injected
into the GC to determine the signal-to-noise (S/N) ratio.
The LOD, defined as a S/N ratio of 3 was 6 ng/g, while the
LOQ, defined as a S/N ratio of 10, was 20.0 ng/g.
Table 2 brings together the myristicin concentrations in
human plasma samples taken from volunteers who con-
sumed the alcoholic solution of myristicin standard 1 h
before sampling. The observed differences in myristicin
plasma concentration result from the different metabolisms
of the volunteers connected with their age, sex, weight, etc.
The estimated myristicin concentrations in human plasma
are much higher than the LOQ, although the administered
myristicin doses were significantly below the amount
believed to cause negative symptoms in humans.
Conclusions
The analytical procedure of myristicin determination in rat
serum described in the literature involves deproteinization,
separation, and fractionation concentration by switching of
columns in the HPLC system [15]. However, it should be
stressed that the removal of serum proteins in the HPLC
process can lead to the loss of the analytes forming ana-
lyte–protein complexes.
The present report describes the rapid, simple, and
useful procedure of myristicin analysis in human serum,
involving myristicin–protein complex degradation before
chromatographic analysis. The method is characterized by
a high recovery (above 99 %) and a low detection limit of
6.0 ng/g, which to date are the most satisfactory values
reported in the literature for myristicin determination in
plasma [14, 15]. The analysis was achieved by dilution of
the plasma alcoholic solution to reach a final alcohol
concentration of less than 40 %. The SPE conditions for
myristicin isolation from human plasma solutions agree
with those elaborated for the isolation of low-molecular
oxygen compounds from essential oils [19]. After slight
tuning, the described method can be adapted for the
determination of myristicin in other biofluids, such as
cerebral spinal fluid and urine samples.
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